Back to Search
Start Over
Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017–2019.
- Source :
-
Osteoporosis International . May2024, Vol. 35 Issue 5, p775-783. 9p. - Publication Year :
- 2024
-
Abstract
- Summary: With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years. Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years. Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017–2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan–Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups. Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. Analysis for specific fractures showed a lower hazard of hip fracture in the SERM + VitD group (HR, 0.25; 95% CI, 0.09–0.71; p = 0.009). No difference was observed between the groups regarding mortality. Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk. [ABSTRACT FROM AUTHOR]
- Subjects :
- *OSTEOPOROSIS prevention
*THERAPEUTIC use of vitamin D
*BONE fracture prevention
*COMBINATION drug therapy
*HOSPITAL mortality
*TREATMENT effectiveness
*BONE fractures
*KAPLAN-Meier estimator
*OSTEOPOROSIS
*SELECTIVE estrogen receptor modulators
*WOMEN'S health
*COMPARATIVE studies
*CONFIDENCE intervals
*PROPORTIONAL hazards models
*REGRESSION analysis
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 0937941X
- Volume :
- 35
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Osteoporosis International
- Publication Type :
- Academic Journal
- Accession number :
- 176726599
- Full Text :
- https://doi.org/10.1007/s00198-024-07022-7